What did we learn about glycemic control achieved with liraglutide in LEADER? Might the differences in glycemic exposure and other metabolic factors explain the reduction on kidney disease?

What did we learn about glycemic control achieved with liraglutide in LEADER? Might the differences in glycemic exposure and other metabolic factors explain the reduction on kidney disease?

What did we learn about the degree of glycemic control achieved with liraglutide in the LEADER trial? And might the differences in glycemic exposure and other metabolic factors explain the reduction on kidney disease?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Vivian Fonseca, MD

Vivian Fonseca, MD

Professor of Medicine and Pharmacology Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Center Past President, Science and Medicine American Diabetes Association